盐酸纳曲酮结构式
|
常用名 | 盐酸纳曲酮 | 英文名 | Naltrexone Hydrochloride |
---|---|---|---|---|
CAS号 | 16676-29-2 | 分子量 | 377.862 | |
密度 | 1.47 g/cm3 | 沸点 | 558.1ºC at 760 mmHg | |
分子式 | C20H24ClNO4 | 熔点 | 274-2760C | |
MSDS | 中文版 美版 | 闪点 | 291.4ºC | |
符号 |
GHS07 |
信号词 | Warning |
盐酸纳曲酮用途盐酸纳曲酮主要用于对已解除阿片类药物毒瘾者的康复期辅助治疗,使戒除阿片瘾者能维正常生活,防止或减少复吸。 |
中文名 | 盐酸纳曲酮 |
---|---|
英文名 | Naltrexone Hydrochloride |
中文别名 | 17-环丙基甲基-4,5-环氧-3,14-二羟基吗啡喃-6-酮盐酸盐 | 纳曲酮盐酸盐 |
英文别名 | 更多 |
密度 | 1.47 g/cm3 |
---|---|
沸点 | 558.1ºC at 760 mmHg |
熔点 | 274-2760C |
分子式 | C20H24ClNO4 |
分子量 | 377.862 |
闪点 | 291.4ºC |
精确质量 | 377.139374 |
PSA | 70.00000 |
LogP | 2.26530 |
外观性状 | 白色结晶粉末 |
蒸汽压 | 2.71E-13mmHg at 25°C |
储存条件 | 2-8°C |
水溶解性 | H2O: 50 mg/mL, clear, colorless |
计算化学 | 1、疏水参数计算参考值(XlogP): 2、氢键供体数量:3 3、氢键受体数量:5 4、可旋转化学键数量:2 5、互变异构体数量:9 6、拓扑分子极性表面积(TPSA):70 7、重原子数量:26 8、表面电荷:0 9、复杂度:621 10、同位素原子数量:0 11、确定原子立构中心数量:4 12、不确定原子立构中心数量:0 13、确定化学键立构中心数量:0 14、不确定化学键立构中心数量:0 15、共价键单元数量:2 |
更多 | 1.性状:未确定 2.密度(g/mL,25/4℃):未确定 3.相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC): 274-2760C 5. 沸点(ºC,常压): 未确定6.沸点(ºC,5.2kPa):未确定 7.折射率:未确定 8.闪点(ºC):未确定 9.比旋光度(º):未确定 10.自燃点或引燃温度(ºC):未确定 11.蒸气压(kPa,25ºC):未确定 12.饱和蒸气压(kPa,60ºC):未确定 13.燃烧热(KJ/mol):未确定 14.临界温度(ºC):未确定 15.临界压力(KPa):未确定 16.油水(辛醇/水)分配系数的对数值:未确定 17.爆炸上限(%,V/V):未确定 18.爆炸下限(%,V/V):未确定 19.溶解性:H2O: 50mg/mL, clear, colorless |
符号 |
GHS07 |
---|---|
信号词 | Warning |
危害声明 | H302 |
警示性声明 | P301 + P312 + P330 |
个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
危害码 (欧洲) | Xn: Harmful; |
风险声明 (欧洲) | R22 |
安全声明 (欧洲) | S22-S36 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | QD2160000 |
~74% 盐酸纳曲酮 16676-29-2 |
文献:WO2006/35195 A1, ; Page/Page column 7 ; |
~% 盐酸纳曲酮 16676-29-2 |
文献:US2008/8745 A1, ; Page/Page column 4 ; |
盐酸纳曲酮上游产品 3 | |
---|---|
盐酸纳曲酮下游产品 9 | |
Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies.
Int. J. Pharm. 477(1-2) , 631-42, (2014) Naltrexone hydrochloride (NTX) is an innovative drug used in ophthalmology for treatment of ocular surface diseases such as impaired corneal wound healing and severe dry eye. Poor chemical stability h... |
|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Nat. Chem. Biol. 3(5) , 268-273, (2007) The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain holds promise for the treatment of neurological diseases and has yielded new insight into brain canc... |
|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Nat. Chem. Biol. 5 , 765-71, (2009) Studies of gene function and molecular mechanisms in Plasmodium falciparum are hampered by difficulties in characterizing and measuring phenotypic differences between individual parasites. We screened... |
Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)-, hydrochloride (1:1) |
EINECS 240-723-0 |
(1S,5R,13R,17S)-4-(cyclopropylméthyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadéca-7(18),8,10-trién-14-one chlorhydrate |
MFCD00069324 |
(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadeca-7(18),8,10-trien-14-one hydrochloride |
morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)-, hydrochloride |
(5α)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one hydrochloride (1:1) |
Naltrexone hydrochloride |
Naltrexone HCl |
(5α)-17-(cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one hydrochloride |
(1S,5R,13R,17S)-4-(Cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadeca-7(18),8,10-trien-14-onhydrochlorid |